UK approves AstraZeneca's antibody-based COVID treatment

Britain's medicines regulator has approved AstraZeneca's antibody-based COVID-19 treatment for preventing infections in adults with poor immune response, marking a major step in the fight against the pandemic as infections surge globally. The decision to grant approval for the treatment, Evusheld, was endorsed by the government's independent scientific advisory body, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) said on Thursday. Figures showing a global rise in COVID-19 cases could herald a much bigger problem, the World Health Organization said this week, warning nations to remain vigilant.